NDAORALTABLET
Approved
Feb 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXAQUIN (lomefloxacin hydrochloride) is an oral fluoroquinolone antibiotic approved in 1992 for bacterial infections. It is a small-molecule quinolone that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in susceptible organisms. The drug is indicated for respiratory tract and urinary tract infections caused by susceptible pathogens.
LOE Approaching
Competitive pressure of 30 indicates modest market presence; teams are likely focused on transition planning and maximizing remaining exclusivity rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAXAQUIN offers limited career growth due to its LOE-approaching status and minimal linked job openings. Roles are primarily defensive—managing declining market share, optimizing pricing, and transitioning customers—rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on MAXAQUIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.